The main results from PIONEER 6 were presented at the American Diabetes Association (ADA) 79th Scientific Sessions and simultaneously published in The New England Journal of Medicine (NEJM). Novo Nordisk has announced that the PIONEER 6 trial achieved its primary...
Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive...
Results presented at 24th Congress of EHA in Amsterdam Combination of iadademstat and azacitidine shows good safety profile in elderly AML patients Recommended dose for Phase II established with only six patients Quick onset of response and preliminary clinical...
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology,...
Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability and...
The EndBrainCancer Initiative (EBCI) held its 8thAnnual “Brains Matter” Dinner on May 15th raising $57,500 for its work. The “Hopeless to HOPE” campaign was announced. The goal of this multi-year campaign is to bring new clinical trials for...
Email
Text